MESSINA, SILVIA
 Distribuzione geografica
Continente #
EU - Europa 39
NA - Nord America 19
AS - Asia 18
SA - Sud America 3
OC - Oceania 2
Totale 81
Nazione #
US - Stati Uniti d'America 19
IT - Italia 13
CH - Svizzera 9
SG - Singapore 6
SE - Svezia 5
RU - Federazione Russa 4
CN - Cina 3
FI - Finlandia 3
IN - India 3
JP - Giappone 3
AU - Australia 2
BR - Brasile 2
MY - Malesia 2
PL - Polonia 2
RS - Serbia 2
HU - Ungheria 1
IL - Israele 1
UY - Uruguay 1
Totale 81
Città #
Singapore 6
Caldwell 4
Milan 4
Belgrade 2
Castellina in Chianti 2
Kuala Lumpur 2
Lappeenranta 2
Machida 2
New York 2
Porto Alegre 2
Shanghai 2
Arakawa 1
Basel 1
Boardman 1
Budapest 1
Chennai 1
Decatur 1
Helsinki 1
Jerusalem 1
Lawrence 1
Mancherial 1
Melbourne 1
Montevideo 1
Moscow 1
Naples 1
Princeton 1
Sennori 1
St Louis 1
Vimodrone 1
Warsaw 1
Wroclaw 1
Totale 50
Nome #
Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios 62
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults 14
The value of routine blood work-up in clinical stratification and prognosis of patients with amyotrophic lateral sclerosis 10
Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis 8
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study (Neurology and Therapy, (2024), 13, 3, (611-624), 10.1007/s40120-024-00591-z) 4
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study 2
Totale 100
Categoria #
all - tutte 626
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 626


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202221 0 0 0 0 0 0 0 0 0 0 16 5
2022/202330 7 4 1 4 3 4 1 3 0 0 0 3
2023/202434 0 3 1 3 2 3 9 3 5 1 2 2
2024/202515 9 6 0 0 0 0 0 0 0 0 0 0
Totale 100